title: Haemostasis and pregnancy.
abstract: Normal pregnancy is associated with profound alterations in the coagulation and fibrinolytic systems. While these physiological procoagulant changes are aimed to minimise intrapartum blood loss, they do increase the risk of thromboembolism during pregnancy and the post-partum period. In contrast and more rarely, haemorrhage due to an underlying inherited or acquired bleeding disorder may occur and complicate a pregnancy. Based on an analysis of the literature data, this review presents an overview of the main thrombotic and haemorrhagic disorders complicating pregnancy.
authors.affiliation: Servizio di Immunoematologia e Trasfusione, Ospedale Policlinico, Piazzale L. Scuro, 10, 37134 Verona, Italy. mfranchini@univr.it
authors.forename: Massimo
authors.initials: M
authors.lastname: Franchini
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy; D001777:Blood Coagulation / Q000187:drug effects; D005260:Female; D017359:HELLP Syndrome / Q000097:blood / Q000188:drug therapy; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D006473:Postpartum Hemorrhage / Q000209:etiology* / Q000517:prevention & control; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000209:etiology* / Q000517:prevention & control; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000188:drug therapy*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control
chemical_list: D000925:Anticoagulants